Han Yan , Haihua Li , Xiayu Chen , Jie Wang , Jiayi Yang , Zhongqiu Xu , Cui Hao , Wei Wang
{"title":"丹酚酸A通过阻断糖蛋白b介导的吸附和膜融合作为单纯疱疹病毒的双重抑制剂","authors":"Han Yan , Haihua Li , Xiayu Chen , Jie Wang , Jiayi Yang , Zhongqiu Xu , Cui Hao , Wei Wang","doi":"10.1016/j.phymed.2025.156910","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The development of novel anti-herpes simplex virus (HSV) agents with high efficacy and low toxicity is great importance. Salvianolic acid A (SAA), a stilbenoid caffeic acid trimer from <em>Salvia miltiorrhiza</em> Bunge roots, has shown broad-spectrum antiviral activities against enterovirus 71 (EV71), pseudorabies virus (PRV), and SARS-CoV-2. However, no studies on its anti-HSV activity have been reported yet.</div></div><div><h3>Purpose</h3><div>To investigate the anti-HSV effects of SAA through both <em>in vitro</em> and <em>in vivo</em> approaches and to elucidate its mechanisms of action.</div></div><div><h3>Methods</h3><div>The anti-HSV effects of SAA in <em>vitro</em> were determined by cytopathic effect (CPE) inhibition assay, western blot assay and viral plaque assay<em>.</em> The virucidal assay, drug affinity responsive target stability (DARTS) assay, cellular thermal shift assay (CETSA) and heparin binding assay investigated SAA’s anti-HSV mechanism. The <em>in vivo</em> anti-HSV efficacy of SAA was evaluated using murine model for intranasal HSV-1 encephalitis and vaginal HSV-2 infection model.</div></div><div><h3>Results</h3><div>SAA suppressed HSV-1 and HSV-2 multiplication in different cells with low toxicity, superior to acyclovir. SAA directly inactivates HSV by disrupting virion membrane. SAA interacts with viral surface glycoprotein B (gB) to block HSV adsorption and entry. SAA treatment significantly improved mice survival, attenuated inflammatory symptoms, and reduced viral titers in HSV-1 and HSV-2 infected mice.</div></div><div><h3>Conclusion</h3><div>SAA possesses significant anti-HSV effects <em>in vitro</em> and <em>in vivo</em> through interaction with gB to block HSV entry and cause HSV particle rupture and inactivation. These findings support its potential as a novel therapeutic agent for herpetic encephalitis and genital herpes.</div></div>","PeriodicalId":20212,"journal":{"name":"Phytomedicine","volume":"143 ","pages":"Article 156910"},"PeriodicalIF":6.7000,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Salvianolic acid A acts as a herpes simplex virus dual inhibitor by blocking glycoprotein B-mediated adsorption and membrane fusion\",\"authors\":\"Han Yan , Haihua Li , Xiayu Chen , Jie Wang , Jiayi Yang , Zhongqiu Xu , Cui Hao , Wei Wang\",\"doi\":\"10.1016/j.phymed.2025.156910\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>The development of novel anti-herpes simplex virus (HSV) agents with high efficacy and low toxicity is great importance. Salvianolic acid A (SAA), a stilbenoid caffeic acid trimer from <em>Salvia miltiorrhiza</em> Bunge roots, has shown broad-spectrum antiviral activities against enterovirus 71 (EV71), pseudorabies virus (PRV), and SARS-CoV-2. However, no studies on its anti-HSV activity have been reported yet.</div></div><div><h3>Purpose</h3><div>To investigate the anti-HSV effects of SAA through both <em>in vitro</em> and <em>in vivo</em> approaches and to elucidate its mechanisms of action.</div></div><div><h3>Methods</h3><div>The anti-HSV effects of SAA in <em>vitro</em> were determined by cytopathic effect (CPE) inhibition assay, western blot assay and viral plaque assay<em>.</em> The virucidal assay, drug affinity responsive target stability (DARTS) assay, cellular thermal shift assay (CETSA) and heparin binding assay investigated SAA’s anti-HSV mechanism. The <em>in vivo</em> anti-HSV efficacy of SAA was evaluated using murine model for intranasal HSV-1 encephalitis and vaginal HSV-2 infection model.</div></div><div><h3>Results</h3><div>SAA suppressed HSV-1 and HSV-2 multiplication in different cells with low toxicity, superior to acyclovir. SAA directly inactivates HSV by disrupting virion membrane. SAA interacts with viral surface glycoprotein B (gB) to block HSV adsorption and entry. SAA treatment significantly improved mice survival, attenuated inflammatory symptoms, and reduced viral titers in HSV-1 and HSV-2 infected mice.</div></div><div><h3>Conclusion</h3><div>SAA possesses significant anti-HSV effects <em>in vitro</em> and <em>in vivo</em> through interaction with gB to block HSV entry and cause HSV particle rupture and inactivation. These findings support its potential as a novel therapeutic agent for herpetic encephalitis and genital herpes.</div></div>\",\"PeriodicalId\":20212,\"journal\":{\"name\":\"Phytomedicine\",\"volume\":\"143 \",\"pages\":\"Article 156910\"},\"PeriodicalIF\":6.7000,\"publicationDate\":\"2025-05-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Phytomedicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0944711325005483\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phytomedicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0944711325005483","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Salvianolic acid A acts as a herpes simplex virus dual inhibitor by blocking glycoprotein B-mediated adsorption and membrane fusion
Background
The development of novel anti-herpes simplex virus (HSV) agents with high efficacy and low toxicity is great importance. Salvianolic acid A (SAA), a stilbenoid caffeic acid trimer from Salvia miltiorrhiza Bunge roots, has shown broad-spectrum antiviral activities against enterovirus 71 (EV71), pseudorabies virus (PRV), and SARS-CoV-2. However, no studies on its anti-HSV activity have been reported yet.
Purpose
To investigate the anti-HSV effects of SAA through both in vitro and in vivo approaches and to elucidate its mechanisms of action.
Methods
The anti-HSV effects of SAA in vitro were determined by cytopathic effect (CPE) inhibition assay, western blot assay and viral plaque assay. The virucidal assay, drug affinity responsive target stability (DARTS) assay, cellular thermal shift assay (CETSA) and heparin binding assay investigated SAA’s anti-HSV mechanism. The in vivo anti-HSV efficacy of SAA was evaluated using murine model for intranasal HSV-1 encephalitis and vaginal HSV-2 infection model.
Results
SAA suppressed HSV-1 and HSV-2 multiplication in different cells with low toxicity, superior to acyclovir. SAA directly inactivates HSV by disrupting virion membrane. SAA interacts with viral surface glycoprotein B (gB) to block HSV adsorption and entry. SAA treatment significantly improved mice survival, attenuated inflammatory symptoms, and reduced viral titers in HSV-1 and HSV-2 infected mice.
Conclusion
SAA possesses significant anti-HSV effects in vitro and in vivo through interaction with gB to block HSV entry and cause HSV particle rupture and inactivation. These findings support its potential as a novel therapeutic agent for herpetic encephalitis and genital herpes.
期刊介绍:
Phytomedicine is a therapy-oriented journal that publishes innovative studies on the efficacy, safety, quality, and mechanisms of action of specified plant extracts, phytopharmaceuticals, and their isolated constituents. This includes clinical, pharmacological, pharmacokinetic, and toxicological studies of herbal medicinal products, preparations, and purified compounds with defined and consistent quality, ensuring reproducible pharmacological activity. Founded in 1994, Phytomedicine aims to focus and stimulate research in this field and establish internationally accepted scientific standards for pharmacological studies, proof of clinical efficacy, and safety of phytomedicines.